{"id":"W3119449300","doi":"10.1016/j.ccell.2020.12.017","title":"Lorlatinib in ALK-Rearranged Lung Cancer","year":2021,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer; Princess Margaret Cancer Foundation; Roche; Open Society Institute; Takeda Canada; Novartis","keywords":"Crizotinib; Lung cancer; Anaplastic lymphoma kinase; Medicine; Internal medicine; Oncology; ALK inhibitor; Interim analysis; Pemetrexed; Adenocarcinoma; Chemotherapy; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004397556,0.0003810123,0.0006791684,0.0001157447,0.00005665875,0.00003543602,0.0001181204,0.0005354704,0.007248782],"category_scores_gemma":[0.000008578329,0.0003412732,0.000206639,0.0002859753,0.00004807652,0.00007346479,0.00003782546,0.001100691,0.00002751716],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001897932,"about_ca_system_score_gemma":0.001675013,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00911181,"about_ca_topic_score_gemma":0.002824066,"domain_scores_codex":[0.9980839,0.00005166629,0.0003580766,0.0006364936,0.0003621379,0.0005077349],"domain_scores_gemma":[0.9990361,0.00005751847,0.000158094,0.0004906,0.0001523487,0.0001053855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002583222,0.00007107382,0.008542531,0.001091805,0.0003325359,0.001373092,0.0007101235,0.00002893648,0.000229403,0.000001294985,0.983625,0.003968394],"study_design_scores_gemma":[0.0027002,0.00003661212,0.001663447,0.001273139,0.001106755,0.000009455142,0.00007854635,0.00006268666,0.0006322715,0.000006028731,0.9920834,0.0003474706],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.003792529,0.1597887,0.00001839902,0.6466957,0.003573769,0.001802006,0.0007303884,0.0001193695,0.1834791],"genre_scores_gemma":[0.009447481,0.0133182,0.0002978656,0.798906,0.009266733,0.002365005,0.002371354,0.0002486676,0.1637787],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.1522103,"threshold_uncertainty_score":0.9999039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02150282214088282,"score_gpt":0.346329649892598,"score_spread":0.3248268277517151,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}